- Open Access
Kinetics of MSC-based enzyme therapy for immunoregulation
Journal of Translational Medicine volume 17, Article number: 263 (2019)
Mesenchymal stromal cells (MSC) demonstrate innate and regulatory immunologic functions and have been widely explored for cell therapy applications. Mechanisms by which MSCs achieve therapeutic effects are theorized, though appropriate dosing and duration of these mechanisms in vivo warrant deeper investigation. One, rapid immunosuppressive function of MSCs is through ectoenzyme expression of CD73 and CD39 which cooperatively hydrolyze inflammatory, extracellular adenosine triphosphate (ATP) to anti-inflammatory adenosine. Extracellular ATP has a key role in autoimmune and inflammatory diseases, which administered MSCs have the potential to modulate in a timescale that is befitting of shorter acting therapeutic function.
In vitro experiments were performed to determine the hydrolysis rates of ATP by MSCs. Through kinetic modeling from experimental results, the rate at which a single cell can metabolize ATP was determined. Based on these rates, the ability of MSCs to downregulate inflammatory signaling pathways was prospectively validated using model system parameters with respect to two different mechanisms: extracellular ATP stimulates lymphocytes to suppress proliferation and induce apoptosis and with co-stimulation, it stimulates monocytes to release pro-inflammatory IL-1β. MSCs were co-cultured with immune cells using transwell inserts and compared to immune cell only groups.
Hydrolysis of ATP was efficiently modeled by first-order enzyme kinetics. For in vitro culture, the rate at which a single cell can hydrolyize ATP is 8.9 nmol/min. In the presence of extracellular ATP, cocultures of MSCs reduced cytotoxicity and allows for proliferation of lymphocytes while limiting IL-1β secretion from monocytes.
Such use of these models may allow for better dosing predictions for MSCs to be used therapeutically for chronic inflammatory diseases such as rheumatoid arthritis, diabetes, pancreatitis, and other systemic inflammatory response syndromes. For the first time, the effect of MSCs on ATP hydrolysis in immune cell response is quantitatively analyzed on a cell-molecule basis by modeling the hydrolysis as an enzyme–substrate reaction. The results also give insight into MSCs’ dynamic response mechanisms to ameliorate effects of extracellular ATP whether it be through positive or negative regulation.
Adenosine triphosphate (ATP) is found at high concentrations intracellularly, which range from 3 to 10 mM, but when concentrations of extracellular ATP are high, this often serves as a warning signal . High concentrations of ATP signal inflammatory pathway activation which can lead to necrosis, apoptosis or secretion of proinflammatory cytokines . Release of ATP can be due to cell lysis, apoptosis, or from live cells through pannexin-1 channels by chemical, mechanical or paracrine signals . This release plays a role in both pathology and exacerbation of chronic inflammatory diseases such as osteoarthritis, rheumatoid arthritis, irritable bowel syndrome, emphysema, COPD and Muck–Wells syndrome [4,5,6].
The effects of ATP on immune cells varies greatly by cell type depending on indication. When CD3+/CD28− T-lymphocytes are exposed to high extracellular ATP concentrations, it has been shown that subset populations respond in different ways: T-regulatory cells are activated and proliferate while apoptosis is induced in CD4+ T-cells . Additionally, when co-stimulated with lipopolysaccharide solution (LPS), monocytes and macrophages are activated by high concentrations of ATP to secrete pro-inflammatory IL-1β . The immune system has innate mechanisms to recognize and respond to extracellular ATP and control inflammasome activation. Purinergic receptors respond to extracellular ATP depending on the concentration where responses to low concentrations are mediated by P2R, intermediate concentrations by P2X1, P2Y2 and others, and very high concentrations above 100 μM are mediated by P2X7 . They allow the cell to mediate a response to ATP, while ectoenzymes ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and ecto-5′-nucleotidase (CD73) hydrolyze ATP to AMP and anti-inflammatory adenosine, respectively. The normal extracellular concentrations of ATP are in the 10 nM range, which is a millionth of what can occur in chronic inflammation. The level of extracellular ATP required for activation of purinergic receptors is around 500 nM, but after extended periods of being exposed to these high concentrations, purinergic enzymes have a lessened effect .
Many indications for which extracellular ATP is present and inducing these immune responses are multi-faceted diseases that require complex treatments. One pharmaceutical treatment method used currently aims to block the P2X receptors which disable the cell from responding, and therefore activating downstream inflammatory pathways. For rheumatoid arthritis, AstraZeneca developed the AZD9056 treatment which is an antagonist for P2X receptors . However, this may be limited by the number of receptors it can block, while the extracellular ATP levels remain high.
In the case of cell-based therapies, mesenchymal stromal cells (MSCs) have been widely explored for their immunomodulatory functions. They have shown promise for osteoarthritis by administering bone marrow MSCs intra-articularly with hyaluronic acid . Systemic injection therapies are also being developed which allow MSC localization in the lungs and spleen to treat patients with autoimmune-associated tissue damage such as multiple sclerosis, polymyositis, atopic dermatitis, and rheumatoid arthritis . MSCs possess intrinsic mechanisms to modulate inflammatory environments, secrete anti-inflammatory soluble factors, and home to injured areas, making them a multi-faceted therapy for treating complex diseases [13,14,15].
Looking specifically at ATP, MSCs are shown to express both ectoenzymes, CD39 and CD73 required for hydrolyzing ATP to adenosine, as shown in Fig. 1 [16,17,18]. When co-cultured with immune cells, MSCs can reduce proliferation and apoptosis of T-lymphocytes in the presence of stimulants but have not been explored for responses caused by ATP stimulation [18, 19]. Additionally, it has been shown that coculturing immune cells with MSCs can alter the expression of CD39 and CD73. MSCs upregulate CD39 expression in the presence of activated T-cells, monocytes up-regulate CD73 and natural killer cells acquire CD73 expression in the presence of MSCs [20,21,22]. This shows that MSCs may not only work to directly reduce inflammation caused by extracellular ATP but help cells to self-regulate as well. However, the dose at which MSCs are needed to have therapeutic efficacy is often characterized based on in vivo results and by typically low persistence once administered . The hydrolysis of extracellular ATP could be a rapid therapeutic mechanism that has immunomodulatory activity within the timescales of MSC persistence.
Here, we explore MSCs ability to hydrolyze ATP to anti-inflammatory adenosine in a quantitative way to explain their response more deeply than just positive or negative. Furthermore, we analyzed the physiologic response of different immune cell types to better understand the effect of extracellular ATP and MSCs as immunomodulators. We demonstrate that ATP hydrolysis to adenosine by MSCs follows first-order enzyme kinetics. The experimentally-derived rates were used to hypothesize physiological responses in immune cells. Co-cultures of MSCs showed that at predicted doses, MSCs can restore proliferation, and prevent apoptosis in lymphocytes as well as suppress monocyte secretion of IL-1β.
Human peripheral blood mononuclear cells (PBMCs) were obtained from the New York Blood Center as leukopacks, following Institutional Review Board (IRB) guidelines. 35 mL aliquots of whole blood were layered on top of 15 mL Ficoll solution (Sigma-Aldrich St. Louis, MO) and centrifuged at 400g for 60 min at 4 °C. PBMCs were collected from the top layer and cryopreserved in 90% Gibco fetal bovine serum (FBS) and 5% dimethyl sulfoxide. Batch verification was performed for each donor to ensure viability, stimulation capability and proliferation. For lymphocyte experiments, PBMCs were thawed and seeded in 24 well plates at 4 million cells/mL of complete RPMI 1640 medium (Fisher Scientific, Waltham, MA), 10% Gibco FBS (ThermoFisher Waltham, MA) and 1% penicillin–streptomycin. For monocyte experiments, PBMCs were thawed and seeded in 24 well plates (Corning, Corning NY) at 3 million cells/mL of complete RPMI 1640 medium, 6% human plasma and 1% penicillin–streptomycin. Monocytes adhered overnight and the following day, the wells were rinsed 3 times with phosphate buffered saline (PBS) to remove non-adherent cells.
Whole bone-marrow was processed according to manufacturer’s protocol to isolate mesenchymal stromal cells (Lonza, Allendale, NJ). Bone-marrow derived mesenchymal stromal cells (MSCs) were cultured in complete media composed of alpha-MEM (ThermoFisher Waltham, MA), 10% Hyclone FBS (GE Life Sciences Pittsburgh, PA), 1% penicillin–streptomycin (ThermoFisher, Waltham, MA), and 2.5 μg/L human basic fibroblast growth factor (Waisman Biomanufacturing, Madison WI). Before experiments, cells were allowed to adhere overnight. Media was changed every other day. For coculture experiments, MSCs were seeded at 50,000 cells per transwell insert for a 24-well plate (Corning, Corning NY) and allowed to adhere overnight in 0.7 mL complete medium.
Characterization of extracellular enzymes
FITC-conjugated CD39 and APC-conjugated CD73 antibodies were used to characterize extracellular expression of purinergic enzymes (BD Biosciences, San Jose, CA). Adherent cells were detached with Trypsin (ThermoFisher, Waltham, MA) and PBMCs were centrifuged for 5 min at 500g. The monoclonal antibodies were incubated in 1 mL cell suspension for 10 min protected from light and rinsed 2 times with 2% bovine serum albumin in PBS. Flow cytometry was performed using BD FACS Canto II and FACS Diva software (BD Biosciences, San Jose, CA). Data was analyzed using FlowJo software (Tree Star, Ashland, OR). Positive staining was gated based on negative control cells that do not express CD39 or CD73.
ATP hydrolysis experiments
To expose cells to extracellular ATP, adenosine 5′-triphosphate disodium salt hydrate (Sigma-Aldrich, St. Louis, MO) was reconstituted in sterile, distilled water at a concentration of 50 mM, aliquoted and stored at – 20 °C. Adherent cells were seeded in various well plates at a density of 25,000 cells/cm2 and allowed to adhere overnight. Well plate sizes used were 6, 12, 24, 48 and 96-well. The following day, exposure media was prepared by diluting the ATP solution in media at concentrations ranging from 16 to 560 µM (nmol/mL). Culture media was aspirated and replaced with exposure media.
Time 0 began when soluble ATP containing-media was added to the cells. Then, after each hour of exposure, 10 µL from each well was sampled and transferred to a 96-well plate. A luciferase reagent was optimized to contain 10 mM d-Luciferin substrate (Fisher Scientific, Waltham, MA), 14 mg/mL Renilla Luciferase (Sigma-Aldrich, St. Louis, MO), 100 mM magnesium chloride (Sigma-Aldrich, St. Louis, MO), and sterile, distilled water. 95 µL of the luciferase reagent was added to each well of the 96-well plate, protected from light and shaken for 10 s, before being read using the VarioSkan plate reader (ThermoFisher, Waltham, MA) with luminescence parameters and ATP standards and controls. Because of the short half-life of ATP, standards were used at each timepoints and used to convert relative light units to nmol/mL of ATP. The amount hydrolyzed in each well was calculated by subtracting the remaining amount in individual wells at each timepoint from the initial concentration.
To determine the amount of adenosine being produced as a product of ATP hydrolysis, a fluorometric adenosine assay kit was used according to manufacturer’s protocol (Abcam, Cambridge, UK). In brief, 50,000 MSCs were seeded in a 24-well plate and allowed to adhere overnight. Cells were dosed with 500 nmol of ATP and supernatant was sampled starting after 30 min to 2.5 h of exposure and assayed in duplicate for adenosine concentration.
To correlate ATP hydrolysis with CD39 and CD73 enzymatic activity, ENTPD-1&2 inhibitor POM-1 (Tocris Bio, Bristol, UK) was used at a concentration of 100 µM. Cells were treated for 20 min with POM-1 solution and was removed before ATP dosing. Inhibition of hydrolysis was measured using the adenosine assay rather than ATP assay, as POM-1 is known to interfere with luciferase-based ATP assays .
Non-linear regression models
Using the ATP hydrolysis over time, the total amount hydrolyzed after 90 min was used to determine the rate of hydrolysis for different substrate concentrations. Using non-linear regression fit in Matlab, data was fit to a Michaelis Menton model for each of the population sizes to determine the maximum hydrolysis rate (Vmax) and substrate concentration at half the maximum (Km) when cells were seeded in 6, 12, 24, 48 and 96-well plates. The Vmax values were plotted as a function of the normalized cell population size (*mL/cm2) and fit with a linear curve.
PBMCs were thawed and stained with 2.5 µM CFSE (ThermoFisher, Waltham, MA), a cell permeable fluorescent staining dye, which dilutes in intensity as cells proliferate, at 2 million cells/mL for 5 min protected from light. After 2 PBS rinses, cells were seeded in 24-well plates with a total volume of 0.6 mL complete media and cultured overnight in 24-well plates at 2 million cells/mL. The following day, they were stimulated with 500 ng/mL and 250 ng/mL of anti-CD3 and anti-CD28 monoclonal antibodies respectively (Fisher Scientific, Waltham, MA), and a range of soluble ATP from 0.5 to 6 mM.
For co-culture wells, 50,000 MSCs were allowed to adhere overnight in transwell inserts and added to the PBMC cultures at the time of stimulation with anti-CD3/CD28 and ATP. After 8 h, the inserts were removed, and anti-CD3/CD28 stimulation of the PBMCs continued.
96 h after stimulation cells were centrifuged and dead cells were stained with ethidium homodimer-1 (Fisher Scientific, Waltham, MA). A control well for dead cells was used by exposing PBMCs to 50% ethanol solution for 10 min before staining. After 2 PBS rinses, cells were resuspended in 2% bovine serum albumin in PBS and stored on ice. All flow cytometry was performed using the BD Biosciences Canto II. An unstimulated control was used to gate non-proliferative cells and proliferation was determined by a shift from the control as a percentage of cells. A negative control of HEK293 cells were seeded in transwell inserts at the same density of MSCs to show that effects were due to purinergic enzyme expression. Analysis was done in FlowJo and lymphocytes were gated using forward and side scatter plots. Dead cells were gated based on the cytotoxic control.
Monocytes adhered overnight and the following day, cells were stimulated with 1× lipopolysaccharide solution (LPS) (ThermoFisher, Waltham, MA) for 4 h. Soluble ATP ranging from 0.5 to 3 mM was then added to wells for an additional 2 h. For co-culture wells, MSCs in transwell inserts were added to the monocyte cultures at the time of LPS stimulation at a density of 50,000 cells per transwell. After 2 h of ATP stimulation, inserts were removed, and the supernatant was collected and stored at – 20 °C until analysis was performed.
To measure the IL-1beta secretion, a sandwich ELISA was performed according to manufacturer protocols (R&D Systems, Minneapolis, MN). 100 μL of sample was added at 1:1, 1:10 and 1:50 dilutions in duplicates and a standard curve fit to a 4-parameter logistic curve was used to determine the concentration of IL-1β in each well.
All experiments were done in at least triplicate (n = 3) and assay duplicates were used in plate reader experiments such as luminescence and ELISA. For kinetic modeling, least squares regression was used to determine the correlation of fit. For the proliferation experiment, statistical significance was determined using a one-way ANOVA with Tukey’s post hoc analysis. Significance was denoted for p < 0.10 and p < 0.05. To determine statistical significance between monocyte IL-1β secretion, a one-tailed, unpaired t-test was used with significance p < 0.10. All errors bars are represented as ± SD from the mean.
MSCs express the ectoenzymes CD39 and CD73
It has been shown that CD39 and CD73 enzymes are expressed by MSCs and PBMCs, but because these are primary cells, the expression may be batch-dependent and vary in expression level. As shown in Fig. 2a, MSCs highly express CD73 while CD39 is lowly expressed. The level at which these enzymes are expressed has been shown to vary with ATP exposure as well, and here we show that in the experiments carried out, the low levels of CD39 expression either increased when exposed to high levels of ATP or were sufficient in hydrolyzing the amount exposed. Because CD39 is the first sequential step in the reaction and the assay measured the amount of ATP remaining in the well, we can assume what has been hydrolyzed at each timepoint has also been converted to adenosine by abundantly expressed CD73.
MSCS hydrolyze ATP in a substrate dependent manner which follows Michaelis Menton kinetics
As the population size increased, the amount of ATP hydrolyzed by early timepoints also increased and therefore, the range of exposure was adjusted for each group to ensure around 100% hydrolysis within the timespan appropriate for the assay (Fig. 2b, c). The high range of exposure for 25,000 MSCs to hydrolyze is around 80 nmols while it is around 160 nmols for 50,000 cells. For all doses, the rate at which the cells hydrolyze ATP is dose-dependent, which can be seen by the increase in slope in Fig. 2c from 10 to 160 nmol exposure. As expected with the abundant expression of CD73, the levels of adenosine produced as a result of enzyme activity were similar to the amounts of ATP hydrolyzed and increased with time after ATP dosing (Additional file 1: Figure S1A). Levels of adenosine show around 95% conversion of AMP to adenosine by producing 112 nmol adenosine out of 118 nmol ATP measured after 2.5 h. Additionally, the hydrolysis by MSCs can be primarily attributed to CD39 and CD73 activity and by inhibiting CD39 activity with POM-1, there is little to no adenosine produced (Additional file 1: Figure S1B). Interestingly, many fibroblast cell types also express these ectoenzymes, including cancerous fibroblasts, which demonstrates in part how these cells are able to evade immune response: by hydrolyzing ATP to release anti-inflammatory adenosine. We show hydrolysis over time for these cell types is comparable to that of MSCs (Additional file 1: Figure S2).
We hypothesized that MSC hydrolysis must follow enzyme–substrate kinetics, however we expected it follow a more complex kinetic profile than first-order systems. Surprisingly, we show that fitting the experimental data to Michaelis Menton models where the hydrolysis rate (V) is graphed as a function of the ATP dose (substrate), achieves high correlation of fit (R2 > 0.95) for all population sizes tested (Fig. 3a–e). For 10,000 cells/well in a 96-well plate the Vmax predicted by the model is 0.26 nmol ATP/min (Fig. 3a) while for 300,000 cells in a 6-well plate, the Vmax predicted is 8.1 nmol ATP/min (Fig. 3e).
Maximum hydrolysis rate is linearly correlated to the normalized cell population size
To test the predictive power of the model, the hypothetical maximum hydrolysis rate (Vmax) obtained from the graphs for each cell population size was plotted against the normalized population size. As shown in Fig. 3f, the Vmax values predicted provide a linear prediction for increasing with cell population size, where R2 > 0.99. For predictive testing, the slope of the graph can be used to estimate the amount of ATP to be hydrolyzed by a single MSC/min, which was calculated to be 90 fmoles/min or 5.4 pmol/h when operating at the Vmax. In 2D model systems, the correlation shows that scale-out dosing is applicable. This would mean that for 50,000 MSCs in a 24-well plate transwell insert, the maximum amount of ATP that can be hydrolyzed per hour is 71 nmol when operating at the Vmax.
MSCs allowed for lymphocyte proliferation when stimulated with anti-CD3/CD28 and ATP
T-cell proliferation in response to mitogen or cytokine stimulation has been widely explored to show that MSCs are immunosuppressive by preventing T-cell proliferation, but mechanisms are unclear [18,19,20]. For lymphocytes alone, co-stimulation with anti-CD3/CD28 and ATP has been shown to induce a dose-dependent response: 250 nM is enough to activate CD4+ cell proliferation but 1 mM ATP induces apoptosis in these cells while inducing the greatest increase in proliferation of T-regs compared to lower doses . Similarly, we stimulated lymphocytes with anti-CD3/CD28 antibodies and when T-cells are stimulated for 72 h or more, we see an increase in proliferation (data not shown), but when ATP is added, the proliferation compared to the unexposed control decreases at the concentration of ATP increases (Fig. 4b). For lymphocytes that are co-cultured with MSCs for 8 h and then left to be stimulated for 96 total hours, proliferation is restored compared to lymphocyte only wells (gray bars) as shown in Fig. 4b. This was confirmed further by co-culturing a cell type with the lymphocytes that does not express the ectoenzymes CD39 and CD73, HEK293 cells. In this group, the proliferation was similar to low levels seen in the lymphocyte only group. However, the limit for which MSCs can hydrolyze ATP becomes apparent at high concentrations of 3 mM where proliferation is significantly lower than both the 1- and 2-mM exposure group. Furthermore, proliferation in the MSC-PBMC group for both 1- and 2-mM doses was significantly higher than the PBMC only group. At a dose of 1 mM extracellular ATP, MSCs almost completely restore proliferation to levels seen by anti-CD3/CD28 stimulation alone. Coincidentally, the mean level of proliferation in the MSC-PBMC group exposed to 2 mM ATP is very similar to that of PBMC only exposed to 1 mM. This begins to show the limitation of how much ATP the MSCs can hydrolyze. Contrary to the results seen previously, co-stimulation with anti-CD3/CD28 antibodies and ATP decreases lymphocyte proliferation, which may because T-regs were not isolated, so this relatively high concentration of ATP for CD4+ T-cells would elicit apoptosis, but in the presence of MSCs, it allows CD4+ cells to persist and proliferate by ameliorating the cytotoxic effects of ATP.
MSCs reduce lymphocyte death when exposed to increasing concentrations of ATP
Previous experimental studies have demonstrated that when CD4+ T-cells are exposed to high concentrations of extracellular ATP, apoptosis is induced, while T-regs are resistant to apoptosis at a 1 mM concentration . To exhibit this phenomenon when MSCs are present to relieve the lymphocytes of ATP effects, we compared cell death of PBMC monocultures to PBMC-MSC co-cultures. In the monocultures, Fig. 4c shows that as concentration of ATP increases, cell death increases, but in the presence of MSCs, cell death is reduced. The effects of ATP exposure on lymphocyte cell death were greatest at concentrations of 3 mM, which in the lower range of what extracellular concentrations can reach in chronic inflammatory diseases. With the model, the predicted amount of ATP that 50,000 MSCs can hydrolyze in 8 h is 572 nmol, which in a 24-well plate is equivalent to 1 mM concentration. This is reinforced in the cytotoxicity result because at 1 mM (equivalent to 500 nmol in 0.5 mL), cytotoxicity in the MSC-PBMC group, while not statistically significant, is maintained around the control value. Additionally, cytotoxicity starts to increase at 2- and 3-mM concentrations in the MSC-PBMC group but not as high as PBMCs only. MSC protection from cell death in the presence of ATP is seen at doses which the MSCs can hydrolyze, but not at greater doses. Limiting exposure to only the first 8 h of the 96-h stimulation strengthens the findings that cell death observed is due to ATP exposure.
MSCs reduce IL-1beta secretion from monocytes when exposed to ATP
Co-stimulation of monocytes with lipopolysaccharide solution (LPS) and ATP induces proinflammatory IL-1β to be secreted. Previous studies have demonstrated a “bell-curve” response for ATP exposure ranging from 100 μM to 5 mM, which has been later confirmed as a result of active secretion rather than passive release . Similarly, our results show that as the concentration of ATP increases, the effects on IL-1β become less apparent as shown in Fig. 5b. However, there are orders of magnitude more IL-1β secretion in LPS-primed monocytes exposed to 500 nmol compared to the control. To show the predictive power of the MSC hydrolysis models, monocytes were co-cultured with MSCs throughout 6 h of stimulation with LPS and ATP and IL-1β secretion was significantly suppressed compared to controls (p < 0.10). This was seen for both the 500 and 1000 nmol exposure groups, but 1500 nmol was too high to elicit IL-1β secretion from monocytes alone. Additionally, the mean secretion in MSC-monocyte groups when exposed to 1000 nmol is higher than in the 500 nmol, reinforcing the predictions from the model that 1000 nmol would be too high of a dose for MSCs to hydrolyze in that timespan.
MSCs as a therapeutic for chronic inflammatory diseases
MSCs have potential in a wide range of indications where inflammation plays a role. Furthermore, ATP is a main contender in these indications and ameliorating the effects of ATP is a promising target through receptor antagonists . As an alternative to blocking ATP receptors, MSCs provide an added benefit through their ability to convert ATP to immunosuppressive adenosine. In addition to ATP-related effects, MSCs have been shown to modulate inflammatory environments, secrete anti-inflammatory soluble factors, and home to injured areas. Here we have shown that in 2D in vitro systems, MSCs exemplify conversion of ATP to immunosuppressive adenosine, but also do so in a way that can be modeled by enzyme kinetics. While we primarily model the hydrolysis of ATP, quantified through an ATP based assay, we found that adenosine production is efficiently taking place at these rates as well. Furthermore, they can help restore immune function in cells that are affected by chronic stress caused by extracellular ATP. They do this in a multifaceted way depending on the cell type, where lymphocytes are protected from cytotoxic effects and allowed to respond through proliferation, while monocytes reduce secretion of proinflammatory IL-1β. There may be more effects produced by MSCs in the presence of ATP that are yet to be explored. Future experiments could investigate the effect of MSCs on immune cell expression of purinergic receptors and how that alters ATP hydrolysis rates.
Translational power of kinetic model
Dosing for cell therapeutics remains a constant challenge. In showing that MSCs follow first-order enzyme kinetics for hydrolyzing ATP, we develop a predictive model to show the maximum amount of ATP a single MSC can hydrolyze. In the 2D systems, predicted rates were observed by exposing MSCs to excessive amounts of ATP and experimentally extracting hydrolysis at maximal rates. This was confirmed with adenosine production to match hydrolyzed ATP amounts as well. Further studies would need to be conducted in 3D model systems, such as bioreactors, to analyze how this model is applicable in vivo. It begins to develop the idea of ATP being a substrate rather than a side effect. Theoretically, this could be applied for other mechanisms related to MSCs, such as soluble factors. This model does not take into account the effect of MSCs on surrounding cells, as has been reported. To absolutely characterize the hydrolysis potential, the other cell types would need to be in co-culture during the hydrolysis time studies. A future study could be done to look at the rate of hydrolysis in the presence of monocytes or lymphocytes.
Physiologic response to extracellular ATP
The dynamic response of MSCs has been exhibited through clinical trials, animal studies and in vitro assays with varying immune cells. Here we show an alternative to pharmaceutical approaches that block ATP receptors, and instead introduce a multipotent therapeutic that converts the ATP to adenosine. The effects of ATP on both lymphocytes and monocytes were shown to differ drastically in that monocytes are induced to secrete IL-1β up to a threshold, while lymphocytes, when co-stimulated with anti-CD3/CD28, are less proliferative and more cytotoxic at very high concentrations of ATP. In the case of monocytes, cells appeared to have a stimulation limit for each they would secrete IL-1β when co-stimulated with LPS and ATP are very high concentrations. However, for the ranges of ATP dosing that did elicit secretion, MSCs showed hydrolysis ability by converting the ATP to adenosine and therefore reducing the amount of IL-1β secreted by the monocytes after just 6 h of co-culture. This limit on ATP stimulation has been previously observed, but the exposure dose is shown to be inconsistent . For the lymphocytes, MSCs have traditionally been used to show decreased lymphocyte proliferation over a timespan of days when stimulants such as IL-2, PHA, and anti-CD3/CD28 are used. However, here we show the dynamic nature of an immune response by showing that extracellular ATP suppressed proliferation, and with MSCs in co-culture to ameliorate effects of ATP, proliferation of lymphocytes is restored. The effect of ATP on lymphocytes has been previously studied to show that there is a threshold for varying populations to induce either apoptosis or proliferation, and here we looked at the lymphocyte population as a whole . At high concentrations of ATP, cytotoxicity is high after 96 h of stimulation, but in the presence of MSCs for only the first 8 h, cell death is prevented significantly. Contrary to effects on monocytes, MSCs may help to allow lymphocytes to continue with a persistent immune response in the presence of extracellular ATP.
Implications in MSC dosing
With a growing number of clinical trials using both allogeneic and autologous MSCs for cell therapy, in vivo persistence is a continuing challenge. Systemic infusions subjects MSCs to a number of stressors that reduce persistence such as shear stress, and nutrient transport limitations . Despite this, MSCs have been shown to provide long-term benefits that extend well beyond their circulation time . Here we show that in a matter of hours, MSCs effect lymphocyte proliferation and cell death days after MSCs were present. This may better model the therapeutic effect of MSCs with systemic infusion because it shows that in the short-term the benefit of MSCs may be acting to allow for lymphocyte proliferation during inflammation rather than suppress it. The transient nature of MSC T-cell suppression has been identified previously through T-cell responsiveness to allo-antigens after removal of MSC co-cultures . Dosing is another challenge as well which with experimental modeling as described, may better help to bridge the gap between in vitro and in vivo data especially given that the timespan of our experiments are within range of MSC circulation times. Many studies have shown MSCs suppressing lymphocyte proliferation after days of co-culture but in showing that proliferation can be restored in the timespan that MSCs may persist, we give insight into more accurate dosing predictions [30,31,32]. Dosing for current clinical MSC therapies are on the order of 1 million cells/kg bodyweight for indications such as graft vs host disease [33,34,35,36]. With the model shown, we show that MSC dose can be predicted as a function of the amount of ATP present. For the lymphocyte experiments, it was calculated that 50,000 MSCs could hydrolyze a maximum of 572 nmol (1 mM for 24-well plates) of ATP in 8 h. The MSC-PBMC with 1 mM ATP group was the only one for both proliferation and cell death that maintained values similar to the control. At doses higher than this, 50,000 MSCs proves to be too little to restore proliferation or completely prevent cell death in lymphocytes. For a dose of 200 million cells delivered intravenously, theoretically, approximately 1 mmol of ATP could be hydrolyzed during 1 h. Based on the persistence of cells with this delivery method, it could be determined that this dose is too high or too low based on the amount of extracellular ATP present. To fully understand the dosing for translation in vivo, 3D culture systems could be used to adapt current models for accuracy in volumetric dosing.
With cell-therapy dosing becoming more relevant as MSC therapies continue to emerge, there is a strong need to understand the mechanisms behind these multipotent cells. We show here that for a particular aspect of the inflammatory response, extracellular ATP, dosing can be quantified through experimental kinetic modeling in vitro. Through cell-based assays, the physiological response can be predicted using experimentally derived hydrolysis rates and a dynamic response is uncovered. The predicted outcomes of the functional cell assays were to suppress cytotoxicity, pro-inflammatory cytokine release and proliferation. Contrary to what was expected, we show that proliferation is restored in lymphocytes when co-stimulated with cytokines due to the short exposure time with MSC co-cultures. In all cases, the ability of MSCs to ameliorate the effects of extracellular ATP was exhibited in a dose-dependent manner. Further studies can be done to exploit the translational power of the model in 3D culture settings.
Availability of data and materials
The data generated of analyzed during the current study are available from the corresponding author on reasonable request.
mesenchymal stromal cell
extracellular adenosine triphosphate
chronic obstructive pulmonary disease
cluster of differentiation 4
cluster of differentiation 3
cluster of differentiation 28
peripheral blood mononuclear cells
fetal bovine serum
Roswell Park Memorial Institute
phosphate buffered saline
carboxyfluorescein succinimidyl ester
substrate concentration at half-maximum
human embryonic kidney cell
enzyme-linked immunosorbent assay
analysis of variance
Trautmann A. Extracellular ATP in the immune system: more than just a “danger signal”. Sci Signal. 2009;2(56):e6.
Savio LE, de Andrade Mello P, da Silva CG, Coutinho-Silva R. The P2X7 receptor in inflammatory diseases: angel or demon? Front Pharmacol. 2018;9:52.
Di Virgilio F. Liaisons dangereuses: P2X7 and the inflammasome. Trends Pharmacol Sci. 2007;28(9):465–72.
Chiodetti L, Choi S, Barber DL, Schwartz RH. Adaptive tolerance and clonal anergy are distinct biochemical states. J Immunol. 2006;176(4):2279–91.
Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, et al. ATP drives lamina propria T H 17 cell differentiation. Nature. 2008;455(7214):808.
Bours MJ, Dagnelie PC, Giuliani AL, Wesselius A, Di Virgilio F. P2 receptors and extracellular ATP: a novel homeostatic pathway in inflammation. Front Biosci. 2011;3:1443–56.
Trabanelli S, Očadlíková D, Gulinelli S, Curti A, Salvestrini V, de Paula Vieira R, et al. Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation. J Immunol. 2012;189:1303–10.
Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Melchiorri L, Baricordi OR, Di Virgilio F. Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J Immunol. 1997;159(3):1451–8.
Bours MJL, Swennen ELR, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006;112(2):358–404.
Fitz JG. Regulation of cellular ATP release. Trans Am Clin Climatol Assoc. 2007;118:199–208.
Keystone EC, Wang MM, Layton M, Hollis S, McInnes IB, D1520C00001 Study Team. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012;71(10):1630–5.
Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Nuñez-Córdoba JM, Sánchez-Echenique C, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2016;14(1):246.
Ra JC, Kang SK, Shin IS, Park HG, Joo SA, Kim JG, et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med. 2011;9(1):181.
Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262:509–25. https://doi.org/10.1111/j.1365-2796.2007.01844.x.
Cho KS, Park HK, Park HY, Jung JS, Jeon SG, Kim YK, Roh HJ. IFATS collection: immunomodulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model. Stem Cells. 2009;27:259–65. https://doi.org/10.1634/stemcells.2008-0283.
Lee JJ, Jeong HJ, Kim MK, Wee WR, Lee WW, Kim SU, et al. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function. Purinergic Signal. 2014;10(2):357–65.
Chen M, Su W, Lin X, Guo Z, Wang J, Zhang Q, et al. Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation. Arthritis Rheum. 2013;65(5):1181–93.
Sattler C, Steinsdoerfer M, Offers M, Fischer E, Schierl R, Heseler K, et al. Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transpl. 2011;20(8):1221–30.
William TT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75(3):389–97.
Saldanha-Araujo F, Ferreira FI, Palma PV, Araujo AG, Queiroz RH, Covas DT, et al. Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res. 2011;7(1):66–74.
Monguió-Tortajada M, Roura S, Gálvez-Montón C, Franquesa M, Bayes-Genis A, Borràs FE. Mesenchymal stem cells induce expression of CD73 in human monocytes in vitro and in a swine model of myocardial infarction in vivo. Front Immunol. 2017;8:1577. https://doi.org/10.3389/fimmu.2017.01577.
Chatterjee D, Tufa DM, Baehre H, Hass R, Schmidt RE, Jacobs R. Natural killer cells acquire CD73 expression upon exposure to mesenchymal stem cells. Blood. 2014;123(4):594–5.
Hoogduijn MJ, Roemeling-van Rhijn M, Engela AU, Korevaar SS, Mensah FK, Franquesa M, et al. Mesenchymal stem cells induce an inflammatory response after intravenous infusion. Stem Cells Dev. 2013;22(21):2825–35.
Lu D, Insel PA. Hydrolysis of extracellular ATP by ectonucleoside triphosphate diphosphohydrolase (ENTPD) establishes the set point for fibrotic activity of cardiac fibroblasts. J Biol Chem. 2013;288(26):19040–9.
Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815–22.
Stoffels M, Zaal R, Kok N, van der Meer JW, Dinarello CA, Simon A. ATP-induced IL-1β specific secretion: true under stringent conditions. Front Immunol. 2015;6:54.
Muschler GF, Nakamoto C, Griffith LG. Engineering principles of clinical cell-based tissue engineering. JBJS. 2004;86(7):1541–58.
Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30(1):42–8.
Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101(9):3722–9.
Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11–20.
Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838–43.
Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389–97.
Müller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis. 2008;40(1):25–32.
Fang D, Seo BM, Liu Y, Sonoyama W, Yamaza T, Zhang C, et al. Transplantation of mesenchymal stem cells is an optimal approach for plastic surgery. Stem Cells. 2007;25(4):1021–8.
Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21(8):1733.
Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81(10):1390–7.
This research was conducted with support under Grant Nos. R01GM127353 and R01EB012521 awarded by the National Institutes of Health and the National Institute of General Medical Sciences of the National Institutes of Health under Award Number T32 GM008339.
Ethics approval and consent to participate
Consent for publication
B.P. is a founder and equity holder of Sentien Biotechnologies, Inc whom have licensed patents pertaining to MSC therapeutics. The authors declare no other competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Burr, A., Parekkadan, B. Kinetics of MSC-based enzyme therapy for immunoregulation. J Transl Med 17, 263 (2019) doi:10.1186/s12967-019-2000-6
- Mesenchymal stem cells
- Immune model
- Autoimmune disease
- Cell therapy